1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 Stauffer, M.E. Skelton, N.J. Fairbrother, W.J. http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic C3 H7 N O2 89.093 y ALANINE L-peptide linking C6 H15 N4 O2 1 175.209 y ARGININE L-peptide linking C4 H8 N2 O3 132.118 y ASPARAGINE L-peptide linking C4 H7 N O4 133.103 y ASPARTIC ACID L-peptide linking C3 H7 N O2 S 121.158 y CYSTEINE L-peptide linking C5 H10 N2 O3 146.144 y GLUTAMINE L-peptide linking C5 H9 N O4 147.129 y GLUTAMIC ACID L-peptide linking C2 H5 N O2 75.067 y GLYCINE peptide linking C6 H10 N3 O2 1 156.162 y HISTIDINE L-peptide linking C6 H13 N O2 131.173 y LEUCINE L-peptide linking C6 H15 N2 O2 1 147.195 y LYSINE L-peptide linking C9 H11 N O2 165.189 y PHENYLALANINE L-peptide linking C5 H9 N O2 115.130 y PROLINE L-peptide linking C3 H7 N O3 105.093 y SERINE L-peptide linking C4 H9 N O3 119.119 y THREONINE L-peptide linking C5 H11 N O2 117.146 y VALINE L-peptide linking NE J.BIOMOL.NMR JBNME9 0800 0925-2738 23 57 61 10.1023/A:1015346504499 12061718 Refinement of the Solution Structure of the Heparin-binding Domain of Vascular Endothelial Growth Factor using Residual Dipolar Couplings 2002 UK Structure STRUE6 2005 0969-2126 6 637 648 10.1016/S0969-2126(98)00065-3 Solution Structure of the Heparin-binding Domain of Vascular endothelial Growth Factor 1998 10.2210/pdb1kmx/pdb pdb_00001kmx 1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 1 SINGLE WAVELENGTH M 1 1.0 6496.479 vascular endothelial growth factor heparin-binding domain 1 man polymer no no ARQENPCGPCSERRKHLFVQDPQTCKCSCKNTDSRCKARQLELNERTCRCDKPRR ARQENPCGPCSERRKHLFVQDPQTCKCSCKNTDSRCKARQLELNERTCRCDKPRR A polypeptide(L) n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n human Homo Escherichia sample 9606 Homo sapiens 562 Escherichia coli database_2 pdbx_nmr_software pdbx_struct_assembly pdbx_struct_oper_list repository Initial release Version format compliance Version format compliance Data collection Database references Derived calculations 1 0 2002-07-24 1 1 2008-04-27 1 2 2011-07-13 1 3 2022-02-23 _database_2.pdbx_DOI _database_2.pdbx_database_accession _pdbx_nmr_software.name 1VGH is the same protein but refined without using residual dipolar coupling restraints 2VGH is the minimized mean corresponding the the same protein refined without residual dipolar coupling restraints RCSB Y RCSB 2001-12-17 REL The structure was refined using 1H-15N dipolar coupling restraints structures with the least restraint violations 100 20 DQF-COSY 2D NOESY 3D_15N-separated_NOESY HNHA DQF-COSY 2D NOESY 2D 15N IPAP-HSQC 2D 15N IPAP HSQC 25 mM sodium acetate; 50 mM sodium chloride 5.5 ambient 300 K 25 mM sodium acetate; 50 mM sodium chloride 5.5 ambient 300 K 25 mM sodium acetate; 50 mM sodium chloride 5.5 ambient 300 K 25 mM sodium acetate; 50 mM sodium chloride 5.5 ambient 300 K The structures are based on 459 NOE-derived distance restraints, 28 H-bond restraints, 66 dihedral angle restraints, and 38 residual dipolar coupling restraints torsion angle dynamics 1 fewest violations 2.0 mM VEGF heparin-binding domain; 25 mM sodium acetate; 50 mM sodium chloride, 0.02% sodium azide 90% H2O/10% D2O 2.0 mM VEGF heparin-binding domain U-15N; 25 mM sodium acetate; 50 mM sodium chloride, 0.02% sodium azide 90% H2O/10% D2O 2.0 mM VEGF heparin-binding domain U-15N; 25 mM sodium acetate; 50 mM sodium chloride, 0.02% sodium azide 99.9% D2O 0.6 mM VEGF heparin-binding domain U-15N; 25 mM sodium acetate; 50 mM sodium chloride; 0.02% sodium azide 4:1:0.2 ditridecanoyl-phosphatidylcholine/dihexanoyl-phosphatidylcholine/cetyltrimethylammonium bromide, 5% w/v total lipid in 90% H2O, 10% D2O collection UXNMR collection XwinNMR processing Felix data analysis Felix structure solution CNX Molecular Simulations, Inc. refinement CNX 500 Bruker AMX 500 Bruker DRX ALA 1 n 1 ALA 1 A ARG 2 n 2 ARG 2 A GLN 3 n 3 GLN 3 A GLU 4 n 4 GLU 4 A ASN 5 n 5 ASN 5 A PRO 6 n 6 PRO 6 A CYS 7 n 7 CYS 7 A GLY 8 n 8 GLY 8 A PRO 9 n 9 PRO 9 A CYS 10 n 10 CYS 10 A SER 11 n 11 SER 11 A GLU 12 n 12 GLU 12 A ARG 13 n 13 ARG 13 A ARG 14 n 14 ARG 14 A LYS 15 n 15 LYS 15 A HIS 16 n 16 HIS 16 A LEU 17 n 17 LEU 17 A PHE 18 n 18 PHE 18 A VAL 19 n 19 VAL 19 A GLN 20 n 20 GLN 20 A ASP 21 n 21 ASP 21 A PRO 22 n 22 PRO 22 A GLN 23 n 23 GLN 23 A THR 24 n 24 THR 24 A CYS 25 n 25 CYS 25 A LYS 26 n 26 LYS 26 A CYS 27 n 27 CYS 27 A SER 28 n 28 SER 28 A CYS 29 n 29 CYS 29 A LYS 30 n 30 LYS 30 A ASN 31 n 31 ASN 31 A THR 32 n 32 THR 32 A ASP 33 n 33 ASP 33 A SER 34 n 34 SER 34 A ARG 35 n 35 ARG 35 A CYS 36 n 36 CYS 36 A LYS 37 n 37 LYS 37 A ALA 38 n 38 ALA 38 A ARG 39 n 39 ARG 39 A GLN 40 n 40 GLN 40 A LEU 41 n 41 LEU 41 A GLU 42 n 42 GLU 42 A LEU 43 n 43 LEU 43 A ASN 44 n 44 ASN 44 A GLU 45 n 45 GLU 45 A ARG 46 n 46 ARG 46 A THR 47 n 47 THR 47 A CYS 48 n 48 CYS 48 A ARG 49 n 49 ARG 49 A CYS 50 n 50 CYS 50 A ASP 51 n 51 ASP 51 A LYS 52 n 52 LYS 52 A PRO 53 n 53 PRO 53 A ARG 54 n 54 ARG 54 A ARG 55 n 55 ARG 55 A author_defined_assembly 1 monomeric 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 1_555 x,y,z identity operation 0.0000000000 0.0000000000 0.0000000000 A N VAL 19 A N VAL 19 A O SER 28 A O SER 28 A N ASN 44 A N ASN 44 A O ARG 49 A O ARG 49 1 A O ARG 55 A O ARG 55 1 Y 2 A O ARG 55 A O ARG 55 1 Y 3 A O ARG 55 A O ARG 55 1 Y 4 A O ARG 55 A O ARG 55 1 Y 5 A O ARG 55 A O ARG 55 1 Y 6 A O ARG 55 A O ARG 55 1 Y 7 A O ARG 55 A O ARG 55 1 Y 8 A O ARG 55 A O ARG 55 1 Y 9 A O ARG 55 A O ARG 55 1 Y 10 A O ARG 55 A O ARG 55 1 Y 11 A O ARG 55 A O ARG 55 1 Y 12 A O ARG 55 A O ARG 55 1 Y 13 A O ARG 55 A O ARG 55 1 Y 14 A O ARG 55 A O ARG 55 1 Y 15 A O ARG 55 A O ARG 55 1 Y 16 A O ARG 55 A O ARG 55 1 Y 17 A O ARG 55 A O ARG 55 1 Y 18 A O ARG 55 A O ARG 55 1 Y 19 A O ARG 55 A O ARG 55 1 Y 20 A O ARG 55 A O ARG 55 1 Y 1 A GLN 3 -160.20 -71.95 1 A GLU 4 68.09 79.42 1 A CYS 10 -91.73 -71.97 1 A SER 11 -90.55 -159.16 1 A GLU 12 -125.04 -70.82 1 A ARG 14 -94.96 58.72 1 A ARG 54 -163.65 -69.29 2 A ARG 2 61.61 176.17 2 A PRO 9 -45.43 172.32 2 A CYS 10 -90.31 -82.83 2 A ARG 13 -127.76 -59.40 2 A ARG 14 -90.60 59.22 2 A ARG 54 -159.83 -48.35 3 A PRO 9 -56.61 174.85 3 A CYS 10 -90.10 -79.70 3 A ARG 13 -141.76 -71.49 3 A ARG 14 -158.46 45.22 3 A HIS 16 -161.16 -46.36 3 A PRO 22 -89.68 39.40 3 A GLN 23 -148.82 -49.24 3 A PRO 53 -85.48 -75.09 3 A ARG 54 -154.53 -140.42 4 A ARG 2 60.72 -166.23 4 A GLN 3 58.72 73.61 4 A GLU 4 -141.21 33.98 4 A ARG 14 -67.84 83.51 4 A LYS 15 -41.52 176.55 4 A HIS 16 -153.68 -48.14 4 A ARG 54 -159.14 -92.12 5 A ARG 2 -89.56 -159.57 5 A GLU 4 64.98 112.39 5 A ASN 5 -150.21 85.63 5 A PRO 9 -47.97 178.84 5 A CYS 10 -90.08 -93.65 5 A GLU 12 -141.82 32.17 5 A ARG 13 -150.49 -43.69 5 A ARG 14 -152.61 60.58 5 A LEU 17 -97.08 44.70 5 A ARG 54 -139.16 -54.54 6 A CYS 10 -90.37 -64.83 6 A ARG 13 -138.71 -46.90 6 A ARG 14 -93.47 59.07 6 A ARG 54 -142.42 -69.51 7 A ARG 2 -159.28 -45.58 7 A PRO 6 -58.15 -156.45 7 A PRO 9 -72.45 -169.45 7 A CYS 10 -88.67 -76.16 7 A SER 11 -88.48 -76.80 7 A GLU 12 -156.97 -67.21 7 A ARG 13 -142.36 -48.44 7 A HIS 16 -165.04 -44.95 7 A PRO 22 -91.21 32.52 7 A GLN 23 -137.37 -48.93 7 A ARG 54 -148.28 -63.96 8 A ARG 2 -154.83 35.14 8 A GLU 4 -99.08 43.02 8 A CYS 10 -90.11 -75.02 8 A SER 11 -89.96 -74.54 8 A GLU 12 -162.77 -67.06 8 A ARG 13 -144.37 -49.09 8 A LYS 15 -38.48 137.13 8 A HIS 16 -163.38 -44.44 8 A PRO 22 -91.11 34.91 8 A GLN 23 -142.52 -50.09 9 A ARG 2 -92.82 -63.41 9 A GLN 3 -66.74 -75.10 9 A PRO 6 -61.26 -148.79 9 A PRO 9 -51.43 -175.82 9 A CYS 10 -89.98 -77.26 9 A GLU 12 -158.54 -94.98 9 A ARG 13 -150.56 68.34 9 A ARG 14 178.43 -37.13 9 A LYS 15 -60.77 62.63 9 A ARG 54 -65.86 78.52 10 A GLU 12 77.54 -53.61 10 A LYS 15 -64.01 92.92 10 A PRO 22 -84.02 38.79 10 A GLN 23 -148.77 -48.70 11 A GLN 3 62.08 -157.27 11 A GLU 4 -173.50 16.32 11 A CYS 10 -90.27 -61.64 11 A SER 11 -89.76 -93.14 11 A GLU 12 178.15 -40.39 11 A ARG 13 -144.83 12.89 11 A PRO 22 -89.58 36.91 11 A GLN 23 -150.13 -49.21 12 A SER 11 -59.45 -177.31 12 A ARG 13 -129.33 -165.75 12 A ARG 14 -62.37 85.08 12 A LYS 15 -56.06 72.50 12 A PRO 22 -88.95 40.85 12 A GLN 23 -149.57 -47.71 12 A PRO 53 -72.06 -168.46 13 A ARG 2 -67.06 91.76 13 A GLU 12 -141.59 36.69 13 A ARG 13 -132.94 -75.01 14 A GLU 4 -173.90 129.52 14 A PRO 6 -58.29 -155.97 14 A SER 11 -90.09 -75.36 14 A GLU 12 -175.31 -85.09 14 A ARG 13 -150.63 -59.17 14 A LYS 15 -65.73 69.24 14 A PRO 22 -89.50 32.81 14 A GLN 23 -142.11 -49.93 15 A ARG 2 -162.31 99.94 15 A GLU 12 59.65 -168.18 15 A LYS 15 -44.95 165.29 15 A HIS 16 -168.26 -50.97 15 A PRO 22 -89.91 38.69 15 A GLN 23 -150.40 -48.77 15 A ARG 54 -148.30 -49.64 16 A ARG 2 -156.85 32.39 16 A PRO 9 -50.41 173.35 16 A CYS 10 -90.04 -87.67 16 A GLU 12 -142.86 48.75 16 A ARG 13 -146.94 -75.18 16 A ARG 14 -141.28 37.73 16 A HIS 16 -166.83 -44.64 16 A PRO 22 -90.35 31.10 16 A GLN 23 -135.29 -47.82 16 A ARG 54 -161.08 91.50 17 A ARG 2 60.88 157.08 17 A GLN 3 -101.83 -61.34 17 A GLU 4 -93.98 59.18 17 A ASN 5 -150.19 87.22 17 A PRO 6 -56.74 179.28 17 A PRO 9 -45.15 153.33 17 A GLU 12 -163.58 -164.46 17 A LYS 15 -68.51 65.18 17 A ARG 54 -98.86 -85.95 18 A GLN 3 -65.51 -158.19 18 A GLU 4 67.14 -152.27 18 A SER 11 -91.41 37.53 18 A GLU 12 67.86 -68.20 18 A ARG 13 -146.26 -44.70 18 A LYS 15 -37.14 133.45 18 A HIS 16 -178.47 -43.82 18 A PRO 22 -89.54 33.56 18 A GLN 23 -146.86 -49.41 18 A PRO 53 -79.97 -168.55 19 A GLN 3 -170.50 -168.03 19 A GLU 4 62.81 123.70 19 A CYS 10 -90.56 -64.69 19 A ARG 13 -150.15 -71.08 19 A ARG 14 -158.82 34.48 19 A HIS 16 -166.32 -45.41 19 A ARG 54 -152.37 24.82 20 A PRO 9 -68.02 -175.18 20 A CYS 10 -90.59 -84.76 20 A ARG 13 -150.00 -70.52 20 A PRO 53 -87.25 -72.37 20 A ARG 54 -155.62 -134.87 Heparin-binding Domain from Vascular Endothelial Growth Factor 1 N N A THR 32 A THR 32 HELX_P A ALA 38 A ALA 38 1 1 7 disulf 2.033 A CYS 7 A SG CYS 7 1_555 A CYS 25 A SG CYS 25 1_555 disulf 2.026 A CYS 10 A SG CYS 10 1_555 A CYS 27 A SG CYS 27 1_555 disulf 2.029 A CYS 29 A SG CYS 29 1_555 A CYS 48 A SG CYS 48 1_555 disulf 2.030 A CYS 36 A SG CYS 36 1_555 A CYS 50 A SG CYS 50 1_555 HORMONE/GROWTH FACTOR heparin-binding, angiogenesis, growth factor, HORMONE-GROWTH FACTOR COMPLEX VEGFA_HUMAN UNP 1 137 P15692 ARQENPCGPCSERRKHLFVQDPQTCKCSCKNTDSRCKARQLELNERTCRCDKPRR 137 191 1KMX 1 55 P15692 A 1 1 55 2 2 anti-parallel anti-parallel A PHE 18 A PHE 18 A GLN 20 A GLN 20 A CYS 27 A CYS 27 A CYS 29 A CYS 29 A GLU 42 A GLU 42 A ASN 44 A ASN 44 A ARG 49 A ARG 49 A ASP 51 A ASP 51